Summary
70 / 100 · Bulios Score
What speaks for it
- It holds more cash than debt: 136.6M € against 10.9M €.
- Out of every 100 EUR of revenue, 13 EUR is left as net profit.
- It earns 13 EUR a year on every 100 EUR of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue fell by 4.3% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 13.7 EUR for 1 EUR of yearly profit.
Valuation in detailIs it growing?
It is shrinkingRevenue (EUR)
Diluted EPS (EUR)
- Analyst estimate
Revenue grew by 7.7% a year over 5 years. Over the last 3 years it fell by 4.3% a year. Earnings per share fell by 7.8% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 EUR of revenue goes
- Cost of sales 83 EUR
- Sales and administration 22 EUR
- Taxes and other 0.4 EUR
- Net profit 13 EUR
Net profit, industry median (Medical - Devices) 6.9 EUR
Out of every 100 EUR of revenue, 13 EUR is left as net profit.
Profitability in detailIs it financially healthy?
YesIt could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
Small, safe- Yield
- 1.66%
- Paid out of profit
- 23%
- Raised in a row
- 1 year
You receive $0.29 per share a year. The company covers the payout with ease.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.